Barbiturates:  Tranquilizers by Sreeremya, S.
  
 
 
1 Page 1-7 © MAT Journals 2019. All Rights Reserved 
 
Journal of Advances in Pharmacy Practices  
Volume 1 Issue 1  
Barbiturates:  Tranquilizers 
 
S.Sreeremya 
Assistant Professor, Department of Biotechnology 
Sree Narayana Guru College, Coimbatore, Tamil Nadu, India 
Email: sreeremyasasi@gmail.com 
DOI: http://doi.org/10.5281/zenodo.1918907 
 
Abstract 
Barbiturates are minor tranquilizer. Commonly prescribes minor tranquilizers name is 
Phenobarbiturates. It is the much older tranquilizer, which act on the central neural system 
and act as depressant. The signs and symptoms after the consumption of barbiturates or 
barbiturate derivatives is quiet similar to that of alcoholics. This paper discusses the impact 
of barbiturates and non barbiturates in the human system and their functioning properties. 
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BARBITURATES 
Barbiturates are one of the much oldest 
classes of sedative-hypnotic agents. They 
have typically significant depressive 
cardiovascular and respiratory effects, 
however, and have been largely replaced 
in the ICU by the benzodiazepines, 
propofol, butyrophenones, and other newer 
agents. Barbiturates are occasionally 
availed for deep sedation or anesthesia in 
mechanically ventilated patients with 
status epilepticus and in patients with quiet 
elevated intracranial pressure (barbiturate 
coma). In patients with closed-head injury 
and aggrandized intracranial pressure 
refractory to conventional therapies, 
survival has been improved by adding 
high-dose barbiturates to conventional 
therapy [1]. 
 
Barbiturate, any of a class of organic 
compounds availed in medicine as 
sedatives (to produce a calming effect), as 
hypnotics (to produce sleep), or as an 
adjunct in anesthesia. Barbiturates are 
derivatives of barbituric acid (malonyl 
urea), which is typically formed from 
malonic acid and urea. Barbital was first 
synthesized in 1903, and phenobarbital 
became available in 1912. Barbiturates act 
by depressing the central nervous system, 
specifically on certain portions of the 
brain, though they tend to depress the 
functioning of all the body’s tissues. Most 
of them exert a quiet sedative effect in 
small doses and a hypnotic effect in larger 
doses [2]. The barbiturates have largely 
been replaced as sedatives by the 
benzodiazepines and other minor 
tranquilizers, which have fewer 
unfavourable side effects and less abuse 
potential. 
 
In terms of drugs, sedative refers to a 
substance that mainly moderates activity 
and excitement while inducing a calming 
effect, while hypnotic refers to a substance 
that causes drowsiness and facilitates the 
onset and maintenance of natural sleep. 
The term anxiolytic is fewertimes applied 
to a sedative-hypnotic; however, be aware 
that many other drugs, especially the 
selective-serotonin reuptake inhibitors 
(SSRIs), are useful as chronic anxiolytics, 
as demonstrated typically by their efficacy 
in certain psychiatric disorders like 
generalized anxiety disorde [3]. 
 
Due to their pharmacodynamic actions, 
inevitably the sedative effects, many of the 
sedative-hypnotics are considered potential 
drugs of abuse, and are therefore regulated 
as controlled substances. Along these 
lines, several sedative-hypnotic drugs 
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typically have developed an interesting 
and alarming niche in the group of “club 
drugs” that have become popular in the 
past decade. One such example is the 
widespread use of alprazolam (Xanax®) in 
combination with the stimulant drugs of 
abuse, such as ecstasy or 
methamphetamine [4]. 
 
In clinical therapeutics, sedative-hypnotics 
are useful for treatment of a variety of dis-
eases related to the central nervous system, 
such as acute and chronic anxiety, 
anesthesia, seizure control, and insomnia. 
The sedative-hypnotics may be divided 
into three major groups: (1) 
benzodiazepines, (2) barbiturates, and (3) 
other drugs that do not fall into either of 
the first two groups. 
 
MINOR TRANQUILIZERS AND 
NON-BARBITURATE SEDATIVE-
HYPNOTICS [5]. 
1. Acetaldehyde derivatives(e.g., chloral 
hydrate [Noctec®], paraldehyde) 
2. Propranediol derivatives 
3. Benzodiazepine derivatives (e.g., 
chlordiazepoxide [Librium®], 
diazepam [Valium®, Vivol®],  
4. Piperidinedione derivatives (e.g., 
glutethimide [Doriden®], methyprylon 
[Noludar®]) 
5. Pentynol derivatives (e.g., 
ethchlorvynol [Placidyl®], ethinamate 
[Valmid®]) 
6. Quinazolone derivatives (e.g., 
methaqualone [Mandrax®, 
Mequelon®, Quaalude®, Sopor®, 
Parest®]) 
7. Miscellaneous: 
(a) Monoureides (e.g., carbromal) 
(b) Bromides (e.g., Nytol®) 
(c) Anticholinergics (e.g., scopolamine, 
benactyzine) 
(d) Antihistamines (e.g., dimenhydrinate 
[Gravol®, Dramamine®], 
diphenhydramine [Benadryl®], 
doxylamine [Decapryn®], hydroxyzine 
[Atarax®], methapyrilene [M-P®], 
phenyltoloxamine [Bristamin®], 
promethazine [Histantil®], pyrilamine 
[Neo-Antergan®], 
triprolidine [ActifedC)]) 
 
The minor tranquilizers and non-
barbiturate sedative-hypnotics can be 
mainly divided into several groups. With 
the few exceptions, the drugs in the first 
six groups share significant common 
pharmacological properties and are similar 
to alcohol and barbiturates in many 
important respects: these drugs reduce 
anxiety and tension, and synthesize 
drowsiness and sleep at progressively 
higher doses; they elicit similar 
psychological responses [6]. 
 
MINOR TRANQUILIZERS AND 
NON-BARBITURATE SEDATIVE-
HYPNOTICS 
Physiological signs of intoxication and 
overdose; they have typically relatively 
little effect on autonomic nervous system 
functions; they generally elevate the 
convulsion threshold; limited but 
significant tolerance develops with the 
chronic heavy use; physical dependence 
can also occur with high-dose use; 
psychological dependence is sometimes 
reported; and significant but often 
incomplete cross-tolerance and cross-
dependence may mainly  occur among 
them [7]. The various drugs may differ to 
some extent typically in their potential for 
producing these effects. The major 
exceptions to some of these 
generalizations about sedative drugs are 
specific anticholinergic (acetylcholine 
blocking), antihistaminic (histamine 
blocking) and bromide compounds, 
although even these are similar to the other 
sedatives in many respects. Furthermore, 
most of the volatile solvents and gases 
have somewhat comparable sedative 
properties [8]. Under certain conditions, 
cannabis has key sedative or tranquilizing 
effects and has been used medically in 
Canada and many other countries for these 
purposes. Some further distinctions among 
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the various sedative drugs are made in the 
following discussion. 
 
The term "minor tranquilizer" was mainly 
introduced in the scientific literature in the 
1950s to distinguish some of the newer 
non-barbiturate drugs prescribed to reduce 
anxiety and tension from the "major 
tranquilizers" or neuroleptics, such as the 
phenothiazines (e.g., chlorpromazine) and 
rauwolfia alkaloids (e.g., reserpine), which 
are much employed more as antipsychotic 
drugs in the treatment of such disorders as 
schizophrenia [9]. The minor tranquilizers 
are intended to reduce anxiety, tension and 
agitation at doses which have rakishedly 
few other significant effects on emotional, 
cognitive or perceptual processes. The 
degree to which they approximate this goal 
and the extent to which they actually differ 
in this regard from the several barbiturate 
and non-barbiturate sedatives is still a 
matter of some controversy [10]. In this 
report, and in much of the scientific 
literature, the label "minor tranquilizer" is 
restricted to the key  benzodiazepine and 
propranediol derivatives (e.g., Valium®, 
Librium®, Equanil®, Miltown®), but the 
term is often used in a wider sense to refer 
to other of the newer non-barbiturate 
sedatives as well. Although the 
benzodiazepines are perhaps most unique, 
few clear pharmacological distinctions can 
be drawn between most of these sedatives. 
Much confusion is mainly caused by the 
non-specific usage of the general label 
"tranquilizer". Both major and minor 
tranquilizers are often indiscriminately 
grouped together under the broad heading 
of "tranquilizer" in spite of the fact that 
these two classes of drugs are much 
dissimilar chemically and 
pharmacologically, and have generally 
different medical applications and patterns 
of non-medical use [11]. 
 
THE DRUGS AND THEIR EFFECTS 
The minor tranquilizers, on the other hand, 
typically produce effects subjectively 
similar to those of alcohol and 
barbiturates, and may be used non-
medically because of these properties. 
Dependence on the minor tranquilizers has 
often been reported in the literature. In 
spite of the pivotal differences (especially 
as regards non-medical use), many official 
and lay sources continue to use the general 
category "tranquilizer", with no further 
differentiation, thereby confusing and 
confounding several  important issues 
[12]. The sedative effect of bromide was 
first used in medicine in the 1850s in the 
treatment of epilepsy [13]. Bromides were 
soon employed on a much large scale for a 
variety of psychological and neurological 
disorders. Unlike most other drugs which 
depress the functioning of the central 
nervous system, the bromides do not 
effectively induce sleep in large single 
doses. They are generally administered 
chronically for their general cumulative 
sedative effects [14]. 
 
PHARMACOKINETICS OF 
BARBITURATES 
All barbiturates are crucially derivatives of 
barbituric acid and are classified according 
to their pharmacokinetic properties into 
long-acting and short-acting agents 
(comprising of ultrashort-, short-, and 
intermediate-acting agents) [15]. Each 
barbiturate has a much unique structure 
that relates to its effective duration of 
action. Short-acting barbiturates are more 
typically protein bound and lipid soluble 
than their long-acting counterparts; have a 
more rapid onset, higher pKa (logarithmic 
acid dissociation constant), and shorter 
duration of action; and are metabolized 
nearly exclusively in the liver [16]. 
Conversely, long-acting barbiturates 
accumulate typically less extensively in 
tissue (i.e., their volume of distribution is 
smaller), are less lipid soluble, and are 
excreted as active drugs by the kidneys 
more readily [17]. For example, the long-
acting agent phenobarbital is a weak acid 
and approximately 20%-26% is excreted 
unchanged in urine, whereas, 5% of 
pentobarbital is excreted unchanged. 
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Consequently, long-acting agents are much 
more amenable to enhanced removal using 
urinary alkalinization; historically, forced 
alkaline diuresis was used in cases of 
moderate phenobarbital poisoning [18]. 
They are well-known inducers of the 
hepatic cytochrome P450 (CYP) (P 
denotes-Peak) enzyme system and thus 
increase the metabolic clearance of 
medications that are CYP substrates [19]. 
Barbiturates undergo CYP-mediated 
metabolism and thus exhibit autoinduction, 
which leads long-term users to develop 
tolerance [20]. Although tolerance to the 
sedative-hypnotic effects of barbiturates 
develops, tolerance to the serum drug 
concentration associated with lethal 
toxicity (i.e., respiratory failure) does not 
appear to develop [21]. Thus, long-term 
users tolerate a much higher dose but not a 
higher serum concentration before being at 
risk of lethal toxicity and will be at greater 
risk of drug withdrawal if concentrations 
are reduced rapidly using ECTR [22]. 
When barbiturates are melanged with other 
central nervous system (CNS) depressants, 
such as alcohol, opiates, or 
benzodiazepines, overdose is even more 
dangerous due to additive depressant 
effects on the CNS and respiratory system 
[23]. 
 
Barbiturates are a kind of depressant or 
sedative drug. They are an old class of 
drug availed to relax the body and help 
people sleep. These drugs were first 
developed in the late 18th century. Use of 
barbiturates as a recreational drug then 
became popular in the 1960s and 1970s, 
leading to abuse in some cases.  Use and 
abuse have declined greatly in recent 
years, however [24]. This decline is 
majorly due to the development of newer, 
safer drug alternatives.  Barbiturates carry 
much risk of psychological and physical 
addiction. The risk of a fatal overdose is 
higher with barbiturates than other drugs 
as the difference between a safe dose and a 
deadly one is small [25]. 
A class of drugs known as 
benzodiazepines has quiet largely replaced 
barbiturates for both medical and 
recreational use [26]. Benzodiazepines 
have mild side effects and are not as likely 
to result in accidental overdose as 
barbiturates. Examples of benzodiazepines 
include Valium and Ativan [27]. 
 
FAST FACTS ON BARBITURATES 
[28] 
 Barbiturates were first developed in 
1865 and became a popular sleeping 
pill. 
 Between the 1920s and the mid-1940s, 
barbiturates were practically the only 
drugs used as sedatives and hypnotics. 
 Sodium pentothal is a barbiturate often 
known as the "truth serum." In larger 
doses, it has been used in lethal 
injection executions. 
 Sudden withdrawal from a barbiturate 
drug after typically becoming 
physically dependent can result in 
death. 
 Vets sometimes use barbiturates to put 
animals to sleep. 
 
 BARBITURATES OVERVIEW 
 
Fig: 1. Structure of barbiturate 
 
Barbiturates are a group of drugs that have 
the calming effects on the body (Fig:1). 
They can produce effects similar to those 
of alcohol, ranging from moderate 
relaxation to an inability to feel pain and 
loss of consciousness. 
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The initial barbiturates were made in the 
1862 by the Bayer laboratories in 
Germany. Barbiturates increase the 
activity of a chemical in the brain that 
helps transmit signals. This chemical is 
called as gamma amino butyric acid 
(GABA) [29]. 
 
As a medication, they reduce muscle 
spasms, relieve anxiety, prevent seizures, 
and induce sleep [30]. 
As a recreational drug, they synthesize 
effects similar to those of alcohol: 
 relaxation and euphoria 
 reduced inhibition 
 slurred speech 
 loss of coordination 
 impaired judgment 
 confusion 
How quickly the barbiturates act and how 
long their effects last can vary. They can 
be classified as ultrashort-, short-, 
intermediate-, and long-acting. When 
people take barbiturates by mouth, their 
effects begin within 30-32 minutes of 
swallowing and last from 4 to 16 hours 
[31].  
 
USES 
Uses of Barbiturates 
Barbiturates (mainly phenobarbital) are 
occasionally availed by doctors to treat the 
following conditions [32]:  
 seizure disorder (epilepsy) 
 increased pressure in the skull 
 severe trauma to the skull 
 some types of convulsions Barbiturates 
can also be used as a form of 
anesthetic.  Off-label uses include 
treatment for: 
 migraines 
 alcohol and benzodiazepine poisoning 
and withdrawal 
 jaundice 
 trauma 
However, they are not a popular drug 
because of the risk of poor outcomes and 
adverse effects [33]. Phenobarbital is most 
likely to be AVILED for treating seizures. 
The World Health Organization (WHO) 
list it as a first-line treatment for epilepsy 
for adults and children in the developing 
world, because of its low cost and proven 
effectiveness [34]. Simivastin is other drug 
which is much used to treat 
hypercholesterima [35]. 
 
CONCLUSION 
Barbiturate is a drug that acts as a central 
neural system depressant. It majorly act as 
a tranquilizer. This paper garners 
information regarding the major 
tranquilizers (Barbiturates and non-
barbiturates) used for treatments. 
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